The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc.
Following its phase II stumble of AR-105, Aridis Pharmaceuticals Inc. is dropping its development of the IgG1 monoclonal antibody. The study failed to meet its primary endpoint of showing superiority in clinical cure rates compared to placebo for treating ventilator-associated pneumonia caused by gram-negative Pseudomonas aeruginosa.
In retrospect, it seems inevitable that an algorithm would be appointed to a board of directors. Hong Kong-based Deep Knowledge Ventures named Vital (an acronym for Validating Investment Tool for Advancing Life Sciences) to its board five years ago and credits it with making better decisions than its fellow members, humans all.
In retrospect, it seems inevitable that an algorithm would be appointed to a board of directors. Hong Kong-based Deep Knowledge Ventures named Vital (an acronym for Validating Investment Tool for Advancing Life Sciences) to its board five years ago and credits it with making better decisions than its fellow members, humans all.
With a year-old phase III failure dogging it, Astrazeneca plc's phase III Tulip 2 clinical trial of anifrolumab for treating systemic lupus erythematosus (SLE) met its primary endpoint by reducing disease activity vs. placebo.
The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc.
Winter is coming to the artificial intelligence industry. While it's springtime for investment and technological advancement, gray skies hover over the talent pool.
Astrazeneca plc's Farxiga (dapagliflozin), already the company's fifth best-selling product, now has a heart-failure component. The SGLT2 inhibitor met its phase III study's primary composite endpoint in reducing cardiovascular death or the worsening of heart failure compared to placebo in patients with reduced ejection fraction on standard-of-care treatment, including those with and without type 2 diabetes.